Alvotech Resubmits AVT05 and AVT06 BLAs; Stock Jumps 19% but Regulatory Risk Remains High

What happened

Alvotech shares surged 19% after resubmitting Biologics License Applications for AVT05 (golimumab) and AVT06 (aflibercept) to the FDA, with reviews expected within six months. This follows a Complete Response Letter for AVT05 in November 2025 that cited manufacturing deficiencies at the single Reykjavik facility, triggering a guidance cut and share collapse. The DeepValue report rated Alvotech a 'Wait' at $4.62, highlighting ~$1.1B net debt, negative equity, and unresolved FDA quality issues. While resubmission is necessary, past CRLs for AVT02 and AVT04 underscore the facility's persistent compliance challenges. The stock's rally reflects renewed optimism, but the thin margin of safety demands evidence of sustainable cash generation and regulatory reliability.

Implication

The resubmission reduces the probability of a complete write-off and gives Alvotech a six-month window to demonstrate FDA compliance. However, the base case valuation of $5.75 assumes successful U.S. approvals by late 2026, which remains uncertain. Investors should remain cautious: concentration in a single facility, pending FDA inspection outcomes, and negative equity mean any further setbacks could crush the stock. A position may be warranted only at a deeper discount (~$3.75 attractive entry) or after a clean FDA re-inspection. The bullish scenario of $8.75 requires sustained regulatory reliability, which is not yet confirmed.

Thesis delta

Previously, the thesis centered on the AVT05 CRL as a major overhang, reinforcing the 'Wait' rating. The resubmission introduces a catalyst that could shift the narrative toward regulatory progress, but the fundamental risks – single-site dependency, leverage, and governance concerns – remain largely unchanged. The delta is modest: the potential for U.S. approval within six months improves the odds of the base case, but the bear case of further FDA deficiencies is still alive.